Plumbagin Regulates Snail to Inhibit Hepatocellular Carcinoma Epithelial-Mesenchymal Transition in vivo and in vitro

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• European Association for Study of Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma [published correction appears in Eur J Cancer. 2012 May;48(8):1255-6]. Eur J Cancer. 2012;48(5):599–641. doi:10.1016/j.ejca.2011.12.021
   PubMed Web of Science ®Google Scholar
• McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73(Suppl 1):4–13. doi:10.1002/hep.31288
   PubMed Web of Science ®Google Scholar
• Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–1362. doi:10.1016/S0140-6736(22)01200-4
   PubMed Web of Science ®Google Scholar
• Wang X, Yu GY, Chen M, Wei R, Chen J, Wang Z. Pattern of distant metastases in primary extrahepatic bile-duct cancer: a SEER-based study. Cancer Med. 2018;7(10):5006–5014. doi:10.1002/cam4.1772
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–890. doi:10.1016/j.cell.2009.11.007
   PubMed Web of Science ®Google Scholar
• Navas T, Kinders RJ, Lawrence SM, et al. Clinical evolution of epithelial-mesenchymal transition in human carcinomas. Cancer Res. 2020;80(2):304–318. doi:10.1158/0008-5472.CAN-18-3539
   PubMed Web of Science ®Google Scholar
• Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. Nat Rev Cancer. 2018;18(2):128–134. doi:10.1038/nrc.2017.118
   PubMed Web of Science ®Google Scholar
• Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: a multi-tool for tumor progression. EMBO J. 2021;40(18):e108647. doi:10.15252/embj.2021108647
   PubMed Web of Science ®Google Scholar
• Song S, Qiu X. LncRNA miR503HG inhibits epithelial-mesenchymal transition and angiogenesis in hepatocellular carcinoma by enhancing PDCD4 via regulation of miR-15b [published correction appears in Dig Liver Dis. 2021 Jul 9]. Dig Liver Dis. 2021;53(1):107–116. doi:10.1016/j.dld.2020.09.008
   PubMedGoogle Scholar
• Xiao S, Hu J, Hu N, Sheng L, Rao H, Zheng G. Identification of a novel epithelial-to-mesenchymal-related gene signature in predicting survival of patients with hepatocellular carcinoma. Comb Chem High Throughput Screen. 2022;25(8):1254–1270. doi:10.2174/1386207324666210303093629
   PubMed Web of Science ®Google Scholar
• Pei D, Shu X, Gassama-Diagne A, Thiery JP. Mesenchymal-epithelial transition in development and reprogramming. Nat Cell Biol. 2019;21(1):44–53. doi:10.1038/s41556-018-0195-z
   PubMed Web of Science ®Google Scholar
• Xia P, Zhang H, Xu K, et al. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma. Cell Death Dis. 2021;12(7):691. doi:10.1038/s41419-021-03973-5
   PubMed Web of Science ®Google Scholar
• Fischer KR, Durrans A, Lee S, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015;527(7579):472–476. doi:10.1038/nature15748
   PubMed Web of Science ®Google Scholar
• Zheng X, Carstens JL, Kim J, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527(7579):525–530. doi:10.1038/nature16064
   PubMed Web of Science ®Google Scholar
• Galle E, Thienpont B, Cappuyns S, et al. DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer. Clin Epigenet. 2020;12(1):27. doi:10.1186/s13148-020-0821-z
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang Z, Fang L, et al. Tumor microenvironment composition and related therapy in hepatocellular carcinoma. J Hepatocell Carcinoma. 2023;10:2083–2099. doi:10.2147/JHC.S436962
   PubMed Web of Science ®Google Scholar
• Xutian S, Cao D, Wozniak J, Junion J, Boisvert J. Comprehension of the unique characteristics of traditional Chinese medicine. Am J Chin Med. 2012;40(2):231–244. doi:10.1142/S0192415X12500188
   PubMed Web of Science ®Google Scholar
• Kong D, Zhang F, Shao J, et al. Curcumin inhibits cobalt chloride-induced epithelial-to-mesenchymal transition associated with interference with TGF-β/Smad signaling in hepatocytes. Lab Invest. 2015;95(11):1234–1245. doi:10.1038/labinvest.2015.107
   PubMed Web of Science ®Google Scholar
• Iqbal J, Abbasi BA, Batool R, et al. Potential phytocompounds for developing breast cancer therapeutics: nature’s healing touch. Eur J Pharmacol. 2018;827:125–148. doi:10.1016/j.ejphar.2018.03.007
   PubMed Web of Science ®Google Scholar
• Ijaz S, Akhtar N, Khan MS, et al. Plant derived anticancer agents: a green approach towards skin cancers. Biomed Pharmacother. 2018;103:1643–1651. doi:10.1016/j.biopha.2018.04.113
   PubMed Web of Science ®Google Scholar
• Tripathi SK, Panda M, Biswal BK. Emerging role of plumbagin: cytotoxic potential and pharmaceutical relevance towards cancer therapy. Food Chem Toxicol. 2019;125:566–582. doi:10.1016/j.fct.2019.01.018
   PubMed Web of Science ®Google Scholar
• Yu T, Xu YY, Zhang YY, Li KY, Shao Y, Liu G. Plumbagin suppresses the human large cell lung cancer cell lines by inhibiting IL-6/STAT3 signaling in vitro. Int Immunopharmacol. 2018;55:290–296. doi:10.1016/j.intimp.2017.12.021
   PubMed Web of Science ®Google Scholar
• Pradubyat N, Sakunrangsit N, Mutirangura A, Ketchart W. NADPH: quinone oxidoreductase 1 (NQO1) mediated anti-cancer effects of plumbagin in endocrine resistant MCF7 breast cancer cells. Phytomedicine. 2020;66:153133. doi:10.1016/j.phymed.2019.153133
   PubMed Web of Science ®Google Scholar
• Hafeez BB, Zhong W, Mustafa A, Fischer JW, Witkowsky O, Verma AK. Plumbagin inhibits prostate cancer development in TRAMP mice via targeting PKCε, Stat3 and neuroendocrine markers. Carcinogenesis. 2012;33(12):2586–2592. doi:10.1093/carcin/bgs291
   PubMed Web of Science ®Google Scholar
• Sakunrangsit N, Ketchart W. Plumbagin inhibits cancer stem-like cells, angiogenesis and suppresses cell proliferation and invasion by targeting Wnt/β-catenin pathway in endocrine resistant breast cancer. Pharmacol Res. 2019;150:104517. doi:10.1016/j.phrs.2019.104517
   PubMed Web of Science ®Google Scholar
• Lin Y, Chen Y, Wang S, et al. Plumbagin induces autophagy and apoptosis of SMMC-7721 cells in vitro and in vivo. J Cell Biochem. 2019;120(6):9820–9830. doi:10.1002/jcb.28262
   PubMed Web of Science ®Google Scholar
• Wei Y, Lv B, Xie J, et al. Plumbagin promotes human hepatoma SMMC-7721 cell apoptosis via caspase-3/vimentin signal-mediated EMT. Drug Des Devel Ther. 2019;13:2343–2355. doi:10.2147/DDDT.S204787
   PubMed Web of Science ®Google Scholar
• Wei Y, Yang Q, Zhang Y, et al. Plumbagin restrains hepatocellular carcinoma angiogenesis by suppressing the migration and invasion of tumor-derived vascular endothelial cells. Oncotarget. 2017;8(9):15230–15241. doi:10.18632/oncotarget.14774
   PubMedGoogle Scholar
• Zhong J, Li J, Wei J, et al. Plumbagin restrains hepatocellular carcinoma angiogenesis by stromal cell-derived factor (SDF-1)/CXCR4-CXCR7 axis. Med Sci Monit. 2019;25:6110–6119. doi:10.12659/MSM.915782
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang W, Jin L, Liu S, Liang L, Wei Y. Plumbagin exhibits genotoxicity and induces G2/M cell cycle arrest via ros-mediated oxidative stress and activation of ATM-p53 signaling pathway in hepatocellular cells. Int J Mol Sci. 2023;24(7):6279. doi:10.3390/ijms24076279
   PubMed Web of Science ®Google Scholar
• Zhou R, Wu K, Su M, Li R. Bioinformatic and experimental data decipher the pharmacological targets and mechanisms of plumbagin against hepatocellular carcinoma. Environ Toxicol Pharmacol. 2019;70:103200. doi:10.1016/j.etap.2019.103200
   PubMed Web of Science ®Google Scholar
• Li CM, Zhang J, Wu W, et al. FBXO43 increases CCND1 stability to promote hepatocellular carcinoma cell proliferation and migration. Front Oncol. 2023;13:1138348. doi:10.3389/fonc.2023.1138348
   PubMed Web of Science ®Google Scholar
• Zhang B, Li F, Zhu Z, Ding A, Luo J. CircRNA CDR1as/miR-1287/Raf1 axis modulates hepatocellular carcinoma progression through MEK/ERK pathway. Cancer Manag Res. 2020;12:8951–8964. doi:10.2147/CMAR.S252679
   PubMed Web of Science ®Google Scholar
• Ye Y, Guo J, Xiao P, et al. Macrophages-induced long noncoding RNA H19 up-regulation triggers and activates the miR-193b/MAPK1 axis and promotes cell aggressiveness in hepatocellular carcinoma. Cancer Lett. 2020;469:310–322. doi:10.1016/j.canlet.2019.11.001
   PubMed Web of Science ®Google Scholar
• Kong F, Ma L, Wang X, You H, Zheng K, Tang R. Regulation of epithelial-mesenchymal transition by protein lysine acetylation. Cell Commun Signal. 2022;20(1):57. doi:10.1186/s12964-022-00870-y
   PubMed Web of Science ®Google Scholar
• van Zijl F, Krupitza G, Mikulits W. Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res. 2011;728(1–2):23–34. doi:10.1016/j.mrrev.2011.05.002
   PubMed Web of Science ®Google Scholar
• Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844–855. doi:10.1136/gutjnl-2013-306627
   PubMed Web of Science ®Google Scholar
• Liu CY, Chen KF, Chen PJ. Treatment of Liver Cancer. Cold Spring Harb Perspect Med. 2015;5(9):a021535. doi:10.1101/cshperspect.a021535
   PubMed Web of Science ®Google Scholar
• Zou J, Li H, Huang Q, et al. Dopamine-induced SULT1A3/4 promotes EMT and cancer stemness in hepatocellular carcinoma. Tumour Biol. 2017;39(10):1010428317719272. doi:10.1177/1010428317719272
   Google Scholar
• Giannelli G, Koudelkova P, Dituri F, Mikulits W. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol. 2016;65(4):798–808. doi:10.1016/j.jhep.2016.05.007
   PubMed Web of Science ®Google Scholar
• Trevisani F, Brandi G, Garuti F, et al. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. J Cancer Res Clin Oncol. 2018;144(2):403–414. doi:10.1007/s00432-017-2556-6
   PubMed Web of Science ®Google Scholar
• Khanam A, Kottilil S. New Therapeutics for HCC: does Tumor immune microenvironment matter? Int J Mol Sci. 2022;24(1):437. doi:10.3390/ijms24010437
   PubMed Web of Science ®Google Scholar
• Stefanini B, Ielasi L, Chen R, et al. TKIs in combination with immunotherapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2023;23(3):279–291. doi:10.1080/14737140.2023.2181162
   PubMed Web of Science ®Google Scholar
• Liu X, Li M, Wang X, et al. Effects of adjuvant traditional Chinese medicine therapy on long-term survival in patients with hepatocellular carcinoma. Phytomedicine. 2019;62:152930. doi:10.1016/j.phymed.2019.152930
   PubMed Web of Science ®Google Scholar
• Park J, Jeong D, Song M, Kim B. Recent advances in anti-metastatic approaches of herbal medicines in 5 major cancers: from traditional medicine to modern drug discovery. Antioxidants. 2021;10(4):527. doi:10.3390/antiox10040527
   Web of Science ®Google Scholar
• Li JJ, Liang Q, Sun GC. Traditional Chinese medicine for prevention and treatment of hepatocellular carcinoma: a focus on epithelial-mesenchymal transition. J Integr Med. 2021;19(6):469–477. doi:10.1016/j.joim.2021.08.004
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196. doi:10.1038/nrm3758
   PubMed Web of Science ®Google Scholar
• Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer cells. Science. 2013;342(6159):1234850. doi:10.1126/science.1234850
   PubMed Web of Science ®Google Scholar
• Pinzani M. Epithelial-mesenchymal transition in chronic liver disease: fibrogenesis or escape from death? J Hepatol. 2011;55(2):459–465. doi:10.1016/j.jhep.2011.02.001
   PubMed Web of Science ®Google Scholar
• Jou J, Diehl AM. Epithelial-mesenchymal transitions and hepatocarcinogenesis. J Clin Invest. 2010;120(4):1031–1034. doi:10.1172/JCI42615
   PubMed Web of Science ®Google Scholar
• Liang L, Kaufmann AM. The significance of cancer stem cells and epithelial-mesenchymal transition in metastasis and anti-cancer therapy. Int J Mol Sci. 2023;24(3):2555. doi:10.3390/ijms24032555
   PubMed Web of Science ®Google Scholar
• Seebacher NA, Krchniakova M, Stacy AE, Skoda J, Jansson PJ. Tumour microenvironment stress promotes the development of drug resistance. Antioxidants. 2021;10(11):1801. doi:10.3390/antiox10111801
   Web of Science ®Google Scholar
• Fernando J, Malfettone A, Cepeda EB, et al. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells. Int, J, Cancer. 2015;136(4):E161–E172. doi:10.1002/ijc.29097
   PubMed Web of Science ®Google Scholar
• Yanfei W, Beibei L, Lijie J, et al. Effects of Leucodanone on proliferation, apoptosis, invasion and HIF-1α expression of hepatocellular carcinoma HepG2 cells under hypoxia. Chin Modern Appl Pharm. 2022;33(14):1789–1795.
   Google Scholar
• Alba-Castellón L, Olivera-Salguero R, Mestre-Farrera A, et al. Snail1-dependent activation of cancer-associated fibroblast controls epithelial tumor cell invasion and metastasis. Cancer Res. 2016;76(21):6205–6217. doi:10.1158/0008-5472.CAN-16-0176
   PubMed Web of Science ®Google Scholar
• Long X, Wang DG, Wu ZB, Liao ZM, Xu JJ. Circular RNA hsa_circ_0004689 (circSWT1) promotes NSCLC progression via the miR-370-3p/SNAIL axis by inducing cell epithelial-mesenchymal transition (EMT). Cancer Med. 2023;12(7):8289–8305. doi:10.1002/cam4.5527
   PubMed Web of Science ®Google Scholar
• Hu Y, Li Q, Yi K, et al. HuR affects the radiosensitivity of esophageal cancer by regulating the EMT-related protein snail. Front Oncol. 2022;12:883444. doi:10.3389/fonc.2022.883444
   PubMed Web of Science ®Google Scholar
• Smith BN, Odero-Marah VA. The role of Snail in prostate cancer. Cell Adh Migr. 2012;6(5):433–441. doi:10.4161/cam.21687
   PubMed Web of Science ®Google Scholar
• Wang W, Liu W, Chen Q, Yuan Y, Wang P. Targeting CSC-related transcription factors by E3 ubiquitin ligases for cancer therapy. Semin Cancer Biol. 2022;87:84–97. doi:10.1016/j.semcancer.2022.11.002
   PubMed Web of Science ®Google Scholar
• Tian Y, Qi P, Niu Q, Hu X. Combined snail and E-cadherin predicts overall survival of cervical carcinoma patients: comparison among various epithelial-mesenchymal transition proteins. Front Mol Biosci. 2020;7:22. doi:10.3389/fmolb.2020.00022
   PubMed Web of Science ®Google Scholar
• Steinbichler TB, Dudas J, Ingruber J, et al. Slug is a surrogate marker of Epithelial to Mesenchymal Transition (EMT) in head and neck cancer. J Clin Med. 2020;9(7):2061. doi:10.3390/jcm9072061
   PubMed Web of Science ®Google Scholar
• Maria de França G, Andrade ACM, Felix FA, et al. Survival-related epithelial-mesenchymal transition proteins in oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis. Arch Oral Biol. 2021;131:105267. doi:10.1016/j.archoralbio.2021.105267
   PubMed Web of Science ®Google Scholar
• Wei J, Wu L, Yang S, et al. E-cadherin to N-cadherin switching in the TGF-β1 mediated retinal pigment epithelial to mesenchymal transition. Exp Eye Res. 2022;220:109085. doi:10.1016/j.exer.2022.109085
   PubMed Web of Science ®Google Scholar
• Pettitt J. The cadherin superfamily. WormBook. 2005;1–9. doi:10.1895/wormbook.1.50.1
   PubMedGoogle Scholar
• Liu PF, Kang BH, Wu YM, et al. Vimentin is a potential prognostic factor for tongue squamous cell carcinoma among five epithelial-mesenchymal transition-related proteins. PLoS One. 2017;12(6):e0178581. doi:10.1371/journal.pone.0178581
   PubMed Web of Science ®Google Scholar
• Liu CY, Lin HH, Tang MJ, Wang YK. Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation. Oncotarget. 2015;6(18):15966–15983. doi:10.18632/oncotarget.3862
   PubMedGoogle Scholar
• You H, Yuan D, Bi Y, et al. Hepatitis B virus X protein promotes vimentin expression via LIM and SH3 domain protein 1 to facilitate epithelial-mesenchymal transition and hepatocarcinogenesis. Cell Commun Signal. 2021;19(1):33. doi:10.1186/s12964-021-00714-1
   PubMed Web of Science ®Google Scholar
• Kidd ME, Shumaker DK, Ridge KM. The role of vimentin intermediate filaments in the progression of lung cancer. Am J Respir Cell Mol Biol. 2014;50(1):1–6. doi:10.1165/rcmb.2013-0314TR
   PubMed Web of Science ®Google Scholar
• Xu J, Liu D, Niu H, et al. Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer [published correction appears in J Exp Clin Cancer Res. 2023 Jan 17;42(1):23]. J Exp Clin Cancer Res. 2017;36(1):19. doi:10.1186/s13046-016-0487-8
   PubMed Web of Science ®Google Scholar
• Singh S, Sharma N, Shukla S, et al. Understanding the potential role of nanotechnology in liver fibrosis: a paradigm in therapeutics. Molecules. 2023;28(6):2811. doi:10.3390/molecules28062811
   PubMed Web of Science ®Google Scholar
• Nong J, Glassman PM, Muzykantov VR. Targeting vascular inflammation through emerging methods and drug carriers. Adv Drug Deliv Rev. 2022;184:114180. doi:10.1016/j.addr.2022.114180
   PubMed Web of Science ®Google Scholar
• Mathi Maran S. Bioengineering of nano drug delivery compound to enhance the bioavailability of selected bioactive compound. JABB. 2021;8(3):93–97. doi:10.15406/jabb.2021.08.00259
   Google Scholar
• Zhu J, Qu J, Fan Y, Zhang R, Wang X. Curcumin inhibits invasion and epithelial-mesenchymal transition in hepatocellular carcinoma cells by regulating TET1/Wnt/β-catenin signal axis. Bull Exp Biol Med. 2022;173(6):770–774. doi:10.1007/s10517-022-05629-6
   PubMed Web of Science ®Google Scholar
• Kong ZL, Kuo HP, Johnson A, Wu LC, Chang KLB. Curcumin-loaded mesoporous silica nanoparticles markedly enhanced cytotoxicity in hepatocellular carcinoma cells. Int J Mol Sci. 2019;20(12):2918. doi:10.3390/ijms20122918
   PubMed Web of Science ®Google Scholar
• Wang W, Liu Q, Liang X, Kang Q, Wang Z. Protective role of naringin loaded solid nanoparticles against aflatoxin B1 induced hepatocellular carcinoma. Chem Biol Interact. 2022;351:109711. doi:10.1016/j.cbi.2021.109711
   PubMed Web of Science ®Google Scholar
• Zheng Y, Jia R, Li J, Tian X, Qian Y. Curcumin- and resveratrol-co-loaded nanoparticles in synergistic treatment of hepatocellular carcinoma. J Nanobiotechnology. 2022;20(1):339. doi:10.1186/s12951-022-01554-y
   PubMed Web of Science ®Google Scholar
• Markovsky E, Baabur-Cohen H, Satchi-Fainaro R. Anticancer polymeric nanomedicine bearing synergistic drug combination is superior to a mixture of individually-conjugated drugs. J Control Release. 2014;187:145–157. doi:10.1016/j.jconrel.2014.05.025
   PubMed Web of Science ®Google Scholar
• Wang T, Zhang D, Sun D, Gu J. Current status of in vivo bioanalysis of nano drug delivery systems. J Pharm Anal. 2020;10(3):221–232. doi:10.1016/j.jpha.2020.05.002
   PubMed Web of Science ®Google Scholar